Immunotherapy before surgery for early-stage squamous lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a medication called cadonilimab (an immunotherapy drug) given alone before surgery for people with early-stage squamous cell lung cancer that can be removed. The goal is to see if this treatment can help shrink the tumor and improve outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called squamous cell lung cancer that has not spread too far and can still be removed with surgery.
- Your cancer must be at stage II or IIIA, meaning it is in the lung or nearby lymph nodes but not elsewhere in the body.
- You have not had any prior treatment for this cancer yet.
- You must be in generally good health, able to care for yourself, and have well-functioning organs (like your liver and kidneys).
- You do not have an active autoimmune disease (like lupus or rheumatoid arthritis) that requires medication, and you have not taken immune-suppressing drugs within the last 14 days.
- You should not have had any other cancer within the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemotherapy, given before and after surgery for lung cancer that has very low PD-L1. The goal is to see if this combination helps shrink the tumor and prevents it from coming back.
This trial is testing a combination of two drugs (cadonilimab and anlotinib) given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this approach can shrink the tumor and improve surgical outcomes.
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
This trial tests adding cadonilimab to standard chemotherapy before surgery for esophageal cancer that can be removed. It aims to see if this combination helps shrink the tumor and improve outcomes.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.